Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-003155

Options or other derivatives

  • Chief Financial Officer acquired 84,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Goeltz II Robert C. Chief Financial Officer 2017-01-25 Grant or award · Stock Option (right to buy) +84,000 84,000 D: show line 1 in the form
Loading xslF345X03/doc1.xml…